<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01806337</url>
  </required_header>
  <id_info>
    <org_study_id>DSHNHL-2003-1</org_study_id>
    <secondary_id>German High Grade Lymphoma SG</secondary_id>
    <nct_id>NCT01806337</nct_id>
  </id_info>
  <brief_title>CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma</brief_title>
  <official_title>Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Göttingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus
      PEG-Filgrastim Followed by Alemtuzumab Consolidation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral T cell lymphoma patients of all subtypes according to WHO are treated with an
      induction of 6 cycles of CHOP-etoposide-14 (if below 60 years of age) oder CHOP-14. If at
      least a PR is reached, consolidation with alemtuzumab, total dose 133 mg, is given i.v.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of alemtuzumab consolidation after CHO(E)P 14 induction chemotherapy</measure>
    <time_frame>average of 24 weeks (treatment duration)</time_frame>
    <description>A descriptive approach for the primary endpoint was chosen: Adherence to schedule of alemtuzumab consolidation (number of cycles, dosing, time) - comparison of planned vs given in pts receiving alemtuzumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of complete remissions</measure>
    <time_frame>at week 24 after initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Peripheral T-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Alemtuzumab, antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>alemtuzumab - anti CD 52 antibody administered as consolidation, total dose 133 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Consolidation after CHOP induction</description>
    <arm_group_label>Alemtuzumab, antibody</arm_group_label>
    <other_name>MabCampath</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all risk groups in international prognostic index

          -  diagnosis of aggressive T-cell-lymphoma, confirmed by an excisional biopsy of a lymph
             node or by sufficiently extensive biopsy of an extranodal involvment, if there is no
             lymph node involvment.

          -  these lymphomas comprise: peripheral T-cell lymphoma PTCL-NOS Lennert´s lymphoma
             T-zone lymphoma angioimmunoblastic T-cell-lymphoma

          -  Performance status: ECOG (Eastern Cooperative Oncology Group Score) 0-3(Karnofsky
             index 40-100%)

          -  written consent of the patient

          -  Declaration of center participation

        Exclusion Criteria:

          -  Already initiated lymphoma therapy(exept for the prephase treatment specified for this
             study)

          -  Serious accompanying disorder or impaired organ function

          -  bone marrow involvement&gt;25%

          -  Known hypersensitivity to medications to be used

          -  Know HIV-positivity

          -  Active hepatitis infection, active CMV infection, prior florid tuberculosis

          -  floride systemic infections

          -  suspicion that patient compliance will be poor

          -  Simultaneous participation in any the study protocol

          -  prior chemo-or radiotherapy for malignancy

          -  other concomitant malignant disease

          -  Pregnancy or lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorenz Truemper</last_name>
    <role>Principal Investigator</role>
    <affiliation>German High Grade Non Hodgkin´s Lymphoma Study Group</affiliation>
  </overall_official>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2013</study_first_posted>
  <last_update_submitted>March 6, 2013</last_update_submitted>
  <last_update_submitted_qc>March 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Göttingen</investigator_affiliation>
    <investigator_full_name>Lorenz, Trümper, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>peripheral T cell lymphoma</keyword>
  <keyword>alemtuzumab</keyword>
  <keyword>consolidation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

